Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF monoclonal antibody, alone or associated with chemotherapy, have demonstrated high response rates and prolongation of median and 6-month progression-free survival. Clinical evaluation of several multitarget small molecule tyrosine kinase inhibitors is ongoing. Other promising antiangiogenic compounds are cilengitide and continuous temozolomide. Toxicity is acceptable. Open issues are represented by patterns of tumor progression, resistance mechanisms and biomarkers.

Anti-Angiogenic Approaches to Malignant Gliomas

Riccardo Soffietti
First
;
Elisa Trevisan;Luca Bertero;Chiara Bosa;Roberta Ruda
Last
2012-01-01

Abstract

Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF monoclonal antibody, alone or associated with chemotherapy, have demonstrated high response rates and prolongation of median and 6-month progression-free survival. Clinical evaluation of several multitarget small molecule tyrosine kinase inhibitors is ongoing. Other promising antiangiogenic compounds are cilengitide and continuous temozolomide. Toxicity is acceptable. Open issues are represented by patterns of tumor progression, resistance mechanisms and biomarkers.
2012
12
3
279
288
Riccardo Soffietti;Elisa Trevisan;Luca Bertero;Chiara Bosa;Roberta Ruda
File in questo prodotto:
File Dimensione Formato  
Soffietti 2012 Curr cancer drug targets - Anti-Angiogenic.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 7 MB
Formato Adobe PDF
7 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Soffietti 2012 Current Cancer Drug Targets antiangiogenic approches.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 591.9 kB
Formato Adobe PDF
591.9 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/99562
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact